Jump to navigation Jump to search
Clinical data
Routes of
Pharmacokinetic data
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass192.258 g/mol

4-methoxyphenylpiperazine (Paraperazine, MeOPP, 4-MeOPP) is a piperazine derivative with stimulant effects which has been sold as an ingredient in "Party pills", initially in New Zealand and subsequently in other countries around the world.

MeOPP has been found in vitro to inhibit monoamine re-uptake and stimulate their release. This is a mechanism of action shared with drugs of abuse such as amphetamines, and MeOPP produces somewhat similar effects although it is much less potent and is thought to have relatively insignificant abuse potential. [1] Piperazine derivatives such as TFMPP have also been shown to exert a major part of their mechanism of action as non-selective serotonin agonists, and MeOPP has also been demonstrated to act in this way. [2] MeOPP is anecdotally said to induce significantly less anxiety than similar piperazines, and is usually taken at doses between 120 - 200mg. It does not produce prominent stimulant effects, but is instead said to be relaxing[citation needed], however it is often mixed with stimulant piperazine derivatives such as BZP for a combined effect.

See also

External links


  1. Nagai F, Nonaka R, Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. European Journal of Pharmacology. 2006 Dec 12; [Epub ahead of print]
  2. Maurer HH, Kraemer T, Springer D, Staack RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Therapeutic Drug Monitoring. 2004 Apr; 26(2): 127-31.

Template:Pharmacology-stub Template:WikiDoc Sources